What is NERV (NERV) stock price today?

NERV (NERV) is currently trading at $4.48, down 1.75% today.

What is NERV P/E ratio?

NERV's P/E ratio is -0.19. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NERV return on equity (ROE)?

NERV's return on equity (ROE) is 250.02%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is NERV's market cap?

NERV has a market capitalization of $208.72M.

NASDAQ · Biotechnology

NERV (NERV) Stock

$4.48 -1.75% NASDAQ: NERV Healthcare

Valuation

Metric	Value
Price	$4.48
Market Cap	$208.72M
P/E Ratio	-0.19
P/B Ratio	-1.26
P/S Ratio	0.00
EPS (TTM)	$-34.67
52-Week High	$12.46
52-Week Low	$1.93
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	250.02%
ROA	-414.72%
ROCE	-38.56%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.46
Current Ratio	41.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-45.0M	$-25.0M	$-23.0M	$-22.0M	$-15.0M
Net Profit	$-50.0M	$-32.0M	$-30.0M	$1.0M	$-293.0M
EPS	$-9.35	$-6.01	$-4.61	$0.19	$-34.67
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$77.0M	$55.0M	$57.0M	$37.0M	$98.0M
Total Liabilities	$69.0M	$75.0M	$85.0M	$63.0M	$239.0M
Cash	$61.0M	$36.0M	$41.0M	$21.0M	$82.0M
Borrowings	$0	$0	$0	$0	$65.0M

Latest News

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs GlobeNewswire · Jun 1, 2026 All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy Zacks · May 20, 2026 Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks · May 20, 2026 Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 18, 2026 Minerva Neurosciences: Q1 Earnings Snapshot Associated Press · May 5, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-25.0M	$-25.0M	$-15.0M	$-20.0M	$-13.5B
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$60.0M	$0	$0	$0	$74.4B
Net Cash Flow	$35.0M	$-25.0M	$5.0M	$-20.0M	$60.9B
Free Cash Flow	$-25.0M	$-25.0M	$-15.0M	$-20.0M	$-13.5B

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.58
FCF Yield	-7423.33%
Quick Ratio	20.14
Interest Coverage	0.00
Return 1Y	109.50%
Return 3Y	-58.86%
Return 5Y	-71.44%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLGN	$0.37	-3.94%	-0.48	$4.83M	0.00%
CVKD	$1.51	-13.71%	-0.78	$5.39M	0.00%
ENLV	$1.28	+0.00%	0.03	$21.54M	0.00%
KLTOKlotho Neurosciences, Inc.	$0.38	-7.10%	-1.13	$20.08M	0.00%
NRSN	$0.42	-1.55%	-0.92	$14.85M	0.00%

About NERV

NERV is led by CEO Remy Luthringer, employs 8 people, headquartered in US, publicly traded since 2014.

NERV stock trades at $4.48 with a market capitalization of $208.72M. The stock is valued at a price-to-earnings (P/E) ratio of -0.19, price-to-book of -1.26, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.93 and $12.46, and currently trades 64.0% below its 52-week high.

On profitability, NERV generates a return on equity (ROE) of 250.02% — well above the market average, a sign of a high-quality business, return on capital employed of -38.56%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides